Calhoun Lesley Ann 4
4 · Tango Therapeutics, Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Tango Therapeutics (TNGX) Director Lesley Ann Calhoun Receives Awards
What Happened
Lesley Ann Calhoun, a director of Tango Therapeutics (TNGX), was granted two awards on June 5, 2026: 4,000 restricted stock units (RSUs) and a 25,000-share derivative award (an option/derivative). Both awards show an acquisition price of $0.00 (i.e., no cash paid). These are grants/compensation rather than open-market purchases or sales.
Key Details
- Transaction date: 2026-06-05; Form 4 filed: 2026-06-08 (filed timely).
- Grants reported: 4,000 shares (RSUs) at $0.00; 25,000 shares (derivative) at $0.00.
- Shares owned after transaction: not specified in this filing.
- Footnote F1 (RSUs): Each RSU converts to one share and vests in full on the earlier of June 5, 2027 or the next annual meeting, subject to continuous service.
- Footnote F2 (derivative): The option vests in 12 substantially equal monthly installments over one year, beginning July 5, 2026, subject to continuous service.
- Filing includes Exhibit 24 (Power of Attorney).
Context
RSU grants convert to actual shares only upon vesting; the 25,000-share item is a derivative option that vests monthly (not an immediate sale or cash exercise). Such director awards are common forms of compensation and do not by themselves indicate buying or selling sentiment. This Form 4 was filed within the required reporting window.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-05+4,000→ 16,500 total - Award
Stock Option (Right to Buy)
[F2]2026-06-05+25,000→ 25,000 totalExercise: $20.22Exp: 2036-06-05→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
- [F2]This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.